Effects of ketoprofen on respiratory and circulatory changes in endotoxic shock

Sigurðsson, Gísli H.; Youssef, H.; Banič, Andrej

doi:10.1007/bf01694707

Cited by 8 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pentoxifylline, a TNF inhibitor has been shown to have several beneficial respiratory and haemodynamic effects both in experimental and clinical illnesses (53)(54)(55) and recently it was shown to decreased anorexia, loss of body weight and muscle protein and partially prevented reduction in muscle protein synthesis induced by sepsis (56). Drugs influencing the arachidonic acid cascade such as phospholipase A, inhibitors, prostaglandin E, , prostacyclin, defibrotide, cyclooxygenase inhibitors, lipoxygenase inhibitors, thromboxane A, synthetase and receptor blockers have shown impressive effects on endotoxemia, sepsis and ARDS in various experimental models (49,(57)(58)(59)(60). It is not unlikely that in the future specific indications may be defined for some of these agents in critical illness.…”

Section: Miscellaneousmentioning

confidence: 99%

Prevention of sepsis and multiple organ failure in critically ill patients

Sigurdsson

1995

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

Section: Miscellaneousmentioning

confidence: 99%

Prevention of sepsis and multiple organ failure in critically ill patients

Sigurdsson

1995

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

Rationale for using TNFα and chemotherapy in regional therapy of melanoma

Lejeune¹,

Líénard²,

Eggermont³

et al. 1994

J of Cellular Biochemistry

View full text Add to dashboard Cite

Recombinant tumor necrosis factor-alpha (rTNF alpha) has potent antitumor activity in experimental studies on human tumor xenografts. However, in humans, the administration of rTNF alpha is hampered by severe systemic side-effects. The maximum tolerated dose ranges from 350 to 500 mg/m2, which is at least 10-fold less than the efficient dose in animals. Isolation perfusion of the limbs (ILP) allows the delivery of high dose rTNF alpha in a closed system with acceptable side-effects. A protocol with triple-drug regimen was based on the reported synergism of rTNF alpha with chemotherapy, with interferon-gamma, and with hyperthermia. In melanoma-in-transit metastases (stage IIIA or AB) we obtained a 91% complete response, compared with 52% after ILP with melphalan alone. Release of nanograms levels of TNF alpha in the systemic circulation was evident but control of this leakage and appropriate intensive care resulted in acceptable toxicity. Angiographic, immunohistological, and immunological studies suggest that the efficacy of this protocol is due to a dual targeting: rTNF alpha activates and electively lyses the tumor endothelial cells while melphalan is mainly cytotoxic to the tumor cells. ILP with rTNF alpha appears to be a useful model for studying the biochemotherapy of cancer in man.

show abstract